Leading Technology Group

Scott Needham founded the firm and serves as its CEO, making him the central decision-maker. Joshua (Jim) Landau sits on the board as Non-Executive Director and likely contributes to investment sourcing and governance through his network at TEC and his directorships at Banxa and Elsight. The firm has not disclosed a separate investment committee or external advisory board.

The firm operates as a corporate investor, meaning it deploys its own balance-sheet capital rather than managing third-party funds. The 2022 Crux Biolabs acquisition brought in Genesis Capital as a co-investor, but Leading Technology Group took the majority position, consistent with proprietary capital leading the deal. No regulatory filings indicate the firm raises external commitments.

Jim Landau's chairmanship of an Australian TEC group provides direct access to a curated network of CEOs across industries, a pipeline that likely surfaces proprietary acquisition opportunities. The firm also transacts alongside repeat co-investors — Genesis Capital partnered on the Crux Biolabs deal in 2022, suggesting relationship-driven sourcing rather than auction processes.

Leading Technology Group holds the majority stake in Crux Biolabs, a Melbourne laboratory that provides biomarker and immunological testing for clinical trials. It also owns the Veritus Research Facility, a clinical trial site in Victoria. These are operating subsidiaries, not passive portfolio holdings — the firm controls and operates the businesses directly.

The 2022 Crux Biolabs transaction involved Genesis Capital as a co-investor, so the firm does partner with external capital on specific deals. Beyond that single disclosed instance, no public record indicates whether co-investment rights are routinely offered to outside investors, or whether Genesis was a one-off relationship-driven partner.